Cormorant Private Healthcare Fund II, LP
Insider CIK 1747677 · AVIR 10% owner · RNA 10% owner · AKUS 10% owner · RAIN · OLMA 10% owner · ERAS Director, 10% owner · AVTE · DSGN · MLTX 10% owner · GRNA · GLUE 10% owner · BCAB 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-30 | 2025-10-01 | 5,827 | $6.96 | $40.6K | 1,994,173 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 2,800,000 | $6.61 | $18.51M | 2,000,000 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 3,390,943 | $7.58 | $25.70M | 4,800,000 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 70,748 | $9.38 | $663.6K | 8,423,403 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 232,460 | $8.40 | $1.95M | 8,190,943 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-05 | 2023-10-10 | 58,839 | $59.90 | $3.52M | 8,494,151 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-04 | 2023-10-04 | 67,814 | $57.32 | $3.89M | 8,435,312 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-03 | 2023-10-04 | 150,487 | $57.25 | $8.62M | 8,367,498 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-02 | 2023-10-04 | 74,911 | $57.37 | $4.30M | 8,217,011 | SEC↗ |
| GRNA GreenLight Biosciences Hol | S Sale | 2023-07-20 | 2023-07-24 | 9,188,659 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | A Award deriv | 2023-06-22 | 2023-06-26 | 60,000 | — | $0 | 60,000 | SEC↗ |
| ERAS Erasca, Inc. | P Buy | 2022-12-13 | 2022-12-20 | 307,692 | $6.50 | $2.00M | 10,813,246 | SEC↗ |
| ERAS Erasca, Inc. | P Buy | 2022-12-13 | 2022-12-21 | 307,692 | $6.50 | $2.00M | 10,813,246 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-22 | 4,000,000 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-22 | 1,388,887 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-22 | 4,166,666 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | P Buy | 2021-07-20 | 2021-07-22 | 950,000 | $16.00 | $15.20M | 10,505,553 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion | 2021-07-20 | 2021-07-22 | 9,555,553 | — | $0 | 9,555,553 | SEC↗ |
| AVTE Aerovate Therapeutics, Inc | C Conversion deriv | 2021-07-02 | 2021-07-07 | 1,530,691 | — | $0 | 0 | SEC↗ |
| AVTE Aerovate Therapeutics, Inc | P Buy | 2021-07-02 | 2021-07-07 | 500,000 | $14.00 | $7.00M | 2,030,691 | SEC↗ |
| AVTE Aerovate Therapeutics, Inc | C Conversion | 2021-07-02 | 2021-07-07 | 1,530,691 | — | $0 | 1,530,691 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | C Conversion deriv | 2021-06-28 | 2021-06-30 | 2,124,343 | — | $0 | 0 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | C Conversion deriv | 2021-06-28 | 2021-06-30 | 477,857 | — | $0 | 0 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | P Buy | 2021-06-28 | 2021-06-30 | 600,000 | $19.00 | $11.40M | 3,202,200 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | C Conversion | 2021-06-28 | 2021-06-30 | 2,602,200 | — | $0 | 2,602,200 | SEC↗ |
| RAIN Rain Therapeutics Inc. | C Conversion deriv | 2021-04-27 | 2021-04-29 | 2,512,561 | — | $0 | 0 | SEC↗ |
| RAIN Rain Therapeutics Inc. | P Buy | 2021-04-27 | 2021-04-29 | 450,000 | $17.00 | $7.65M | 2,776,657 | SEC↗ |
| RAIN Rain Therapeutics Inc. | C Conversion | 2021-04-27 | 2021-04-29 | 2,326,657 | — | $0 | 2,326,657 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 1,404,953 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 2,959,891 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion | 2021-03-30 | 2021-04-01 | 4,364,844 | — | $0 | 4,364,844 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2021-03-30 | 2021-04-01 | 750,000 | $20.00 | $15.00M | 5,114,844 | SEC↗ |
| BCAB BioAtla, Inc. | C Conversion deriv | 2020-12-18 | 2020-12-22 | 1,492,060 | — | $0 | 0 | SEC↗ |
| BCAB BioAtla, Inc. | C Conversion | 2020-12-18 | 2020-12-22 | 1,492,060 | — | $0 | 1,492,060 | SEC↗ |
| BCAB BioAtla, Inc. | P Buy | 2020-12-18 | 2020-12-22 | 800,000 | $18.00 | $14.40M | 2,292,060 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | C Conversion deriv | 2020-11-23 | 2020-11-23 | 723,177 | — | $0 | 0 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | C Conversion deriv | 2020-11-23 | 2020-11-23 | 2,122,367 | — | $0 | 0 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | C Conversion | 2020-11-23 | 2020-11-23 | 2,845,544 | — | $0 | 2,845,544 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | P Buy | 2020-11-23 | 2020-11-23 | 425,000 | $19.00 | $8.07M | 3,270,544 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 2,631,580 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 712,250 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 1,650,165 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 1,000,000 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 417,360 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion | 2020-11-03 | 2020-11-05 | 6,411,355 | — | $0 | 6,411,355 | SEC↗ |
| AKUS Akouos, Inc. | C Conversion deriv | 2020-06-30 | 2020-07-02 | 499,989 | — | $0 | 0 | SEC↗ |
| AKUS Akouos, Inc. | P Buy | 2020-06-30 | 2020-07-02 | 290,000 | $17.00 | $4.93M | 789,989 | SEC↗ |
| AKUS Akouos, Inc. | C Conversion | 2020-06-30 | 2020-07-02 | 499,989 | — | $0 | 499,989 | SEC↗ |
| RNA Avidity Biosciences, Inc. | C Conversion deriv | 2020-06-16 | 2020-06-18 | 2,214,545 | — | $0 | 0 | SEC↗ |
| RNA Avidity Biosciences, Inc. | C Conversion | 2020-06-16 | 2020-06-18 | 2,214,545 | — | $0 | 2,214,545 | SEC↗ |
| RNA Avidity Biosciences, Inc. | P Buy | 2020-06-16 | 2020-06-18 | 300,000 | $18.00 | $5.40M | 2,514,545 | SEC↗ |